Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells

International Journal of Nanomedicine

Volumn 3, Issue 3, 2008, Pages 343-350

  Chen, Bao An ^a   Dai, Yong Yuan ^a   Wang, Xue Mei ^a   Zhang, Ren Yun ^a   Xu, Wen Lin ^b   Shen, Hui Ling ^b   Gao, Feng ^a   Sun, Qian ^a   Deng, Xiao Jing ^a   Ding, Jia Hua ^a   Gao, Chong ^a   Sun, Yun Yu ^a   Cheng, Jian ^a   Wang, Jun ^a   Zhao, Gang ^a   Chen, Ning Na ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Daunomycin; Leukemia K562 A02; Multidrug resistance; Nano Au; Nano Fe3O4

Indexed keywords

DAUNORUBICIN; FERRIC OXIDE NANOPARTICLE; GOLD NANOPARTICLE; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FERRIC COMPOUNDS; GOLD; HUMANS; K562 CELLS; LEUKEMIA; NANOPARTICLES;

EID: 69749113002     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Advani R, Saba HI, Tallman MS, et al. 1999. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood, 93:787-95.
2. Lamprecht A, Benoit JP. 2006. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release, 112:208-13.
3. Bennis S, Chapey C, Couvreur P, et al. 1994. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer, 30A:89-93.
4. Bradley G, Juranka PF, Ling V. 1999. Mechanisms of multidrug resistance. Biochimica et Biophysica Acta, 948:87-128.
5. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Drug Delivery, 54:631-51.
6. Chen D, Liao M. 2002. Preparation and characterization of YADH-bound magnetic nanoparticles. J Mol Catal B Enzym, 16:283-91.
7. Cuvier C, Roblot-Treupel L, Millot JM, et al. 1992. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol, 44:509-17.
8. Dresco PA, Zaitsev VS, Gambino RJ, et al. 1999. Preparation and properties of magnetite and polymer magnetite nanoparticles. Langmuir, 15:1945-51.
9. Du D, Ju H, Zhang X, et al. 2005. Electrochemical immunoassay of membrane P-glycoprotein by immobilization cells on gold nanoparticles modified on a methoxysilyl-terminated butyrylchitosan matrix. Biochemistry, 44:11539-45.
10. Farokhzad OC, Khademhosseini A, Jon S, et al. 2005. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem, 77:5453-9.
11. Ferrao P, Sincock P, Cole S, et al. 2001. Intracellular Pgp contributes to functional drug efflux and resistance in acute myeloid leukemia. Leuk Res, 25:395-405.
12. Gao H, Wang J, Shen X, et al. 2004. Preparation of magnetic polybutyl-cyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. World J Gastroenterol, 10:2010-13.
13. Hamada H, Tsuruo T. 1988. Characterization of the ATPase activity of the Mr 170000 to 180000 membrane glycoprotein (Pglycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res, 48:4926-32.
14. Hegewisch-Becker S. 1996. MDR1 reversal: criteria for clinical trails designed to overcome the multidrug resistance phenotype. Leukemia, 10(Suppl 3):S32-8.
15. Jain TK, Morales MA, Sahoo SK, et al. 2005. Iron oxide nanoparticles for sustained delivery anticancer agents. Molecular Pharmaceutics, 2:194-205.
16. Kirchner C, Liedl T, Kudera S, et al. 2005. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett, 5:331-8.
17. Li J, Wang X, Wang C, et al. 2007. The enhancement effect of gold nanoparticles to facilitate the drug delivery and biomarker of drug-resistant cancer cells. Chem Med Chem, 2:374-8.
18. Li J, Wu C, Dai Y, et al. 2007. Doxorubicin-CdS nanoparticles: A potential anticancer agent for enhancing the drug uptake of cancer cells. J Nanosci Nanotechnol, 7:435-9.
19. Litman T, Nielsen D, Skovsgaard T, et al. 1997. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochimica et Biophysica Acta, 1361:159-68.
20. 4 and polylactide nanofibers for application in drug uptake and induction of cell death of leukemia cancer cells. Langmuir, 24:2151-6.
21. Sanford JC, Smith FD, Russell JA. 1993. Optimizing the biolistic process for different biological applications. Methods Enzymol, 217:483-509.
22. Soma CE, Dubernet C, Bentoliba D, et al. 2000. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in poly alkylcyanoacrylate nanoparticles. Biomaterials, 21:1.
23. Suzuki S, Inoue K, Hongoh A, et al. 1997. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukemia cell by an immunoliposome targeting transferring receptor. Br J Cancer, 76:83-9.
24. Tan B, Piwnica-Worms D, Ratner L. 2000. Multidrug resistance transporters and modulation. Curr Opin Oncol, 12:450-8.
25. Tan Y, Li G, Zhao C, et al. 2003. Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leukemia Res, 27:125-31.
26. Twentyman PR. 1992. Cyclosporins as drug resistance modifiers. Biochem Pharmacol, 43:109-17.
27. Vauthier C, Dubernet C, Chauvierre C, et al. 2003. Drug delivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles. J Control Release, 93:151-60.
28. 4) nanoparticles via trichloro-s-triazine. Chem Mater, 18:5401-3.
29. Xu W, Shen H, Ao Z, et al. 2006. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leukemia Res, 30:407-13.
30. Zhang R, Wang X, Wu C, et al. 2006. Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology, 17:3622-6.